Cartesian Therapeutics to Present at the ASGCT 27th Annual Meeting
Cartesian Therapeutics' Rare Disease Candidate Shows Long Lasting Benefit Over Argenx's Vyvgart, Analyst Initiates With Buy
Cartesian Therapeutics Announces New Employment Inducement Grants
Cartesian Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference
GAITHERSBURG, Md., March 28, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the Company), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune...
Cartesian Therapeutics Reports Full Year 2023 Financial Results
Cartesian Therapeutics to Participate in Upcoming Investor Conferences
Cartesian Therapeutics Establishes New Corporate Headquarters
Cartesian Therapeutics Announces New Employment Inducement Grant
GAITHERSBURG, Md., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the œCompany), a clinical-stage biotechnology company developing mRNA cell therapies for the...